Univ.-Prof. Dr. Dr. med. Oliver Söhnlein


Univ.-Prof. Dr. Dr. med. Oliver Söhnlein

Ludwig-Maximilians-University (LMU) Munich
Institute for Cardiovascular Prevention
Pettenkoferstrasse 8a
80336 Munich

Email: oliver.soehnlein(at)med.uni-muenchen.de


Research areas: atherosclerosis, vascular inflammation, innate immunity

Oliver Soehnlein is DZHK Professor for Vascular Immunotherapy at the Institute for Cardiovascular Prevention at the LMU in Munich. His research focuses on the role of myeloid cells in vascular inflammation. On the basis of refined pathophysiological understanding, he aims to design tailored therapeutic approaches.

Research focus

Prof. Soehnlein’s research uses animal models of atherosclerosis to dissect the contribution of neutrophils, the most abundant white blood cells in human circulation, towards inflammatory processes occurring in the arterial vessel wall. His research has provided compelling evidence for the recruitment of neutrophils into atherosclerotic lesions. At the site of inflammation neutrophils fuel important processes underlying atherosclerosis, including the recruitment of additional white blood cells, the activation of these white blood cells as well as the killing of cells within atherosclerotic lesions. Understanding of these mechanisms has enabled him to design preclinical interventional strategies.

Prof. Soehnlein hopes that in the long term his research will not just provide a refined understanding of how arterial inflammation and its complications such as myocardial infarction and stroke occur, but also that his research will provide means of therapeutic interference in human disease.

Additionally, he also holds a Professorship at the Department of Physiology and Pharmacology at the Karolinska Institute in Stockholm, Sweden.

Major achievements and awards

  • Rolf Becker Award, LMU Munich (2019)
  • Albert Fränkel Award, German Society for Cardiology (2019)
  • Outstanding Achievement Award, European Society of Cardiology (2017)
  • Glaxo Smith Kline Basic Science Award (2017)
  • Du Bois-Reymond Award, German Society of Physiology (2014)

Key publications

Silvestre-Roig C, Braster Q, Wichapong K, Lee EY, Teulon JM, Berrebeh N, Winter J, Adrover JM, Santos GS, Froese A, Lemnitzer P, Ortega-Gómez A, Chevre R, Marschner J, Schumski A, Winter C, Perez-Olivares L, Pan C, Paulin N, Schoufour T, Hartwig H, González-Ramos S, Kamp F, Megens RTA, Mowen KA, Gunzer M, Maegdefessel L, Hackeng T, Lutgens E, Daemen M, von Blume J, Anders HJ, Nikolaev VO, Pellequer JL, Weber C, Hidalgo A, Nicolaes GAF, Wong GCL, Soehnlein O. Externalized histone H4 orchestrates chronic inflammation by inducing lytic cell death. Nature. 2019; 569:236-240.

Ferraro B, Leoni G, Hinkel R, Ormanns S, Paulin N, Ortega-Gomez A, Viola JR, de Jong R, Bongiovanni D, Bozoglu T, Maas SL, D'Amico M, Kessler T, Zeller T, Hristov M, Reutelingsperger C, Sager HB, Döring Y, Nahrendorf M, Kupatt C, Soehnlein O. Pro-Angiogenic Macrophage Phenotype to Promote Myocardial Repair. J Am Coll Cardiol. 2019; 73:2990-3002.

Winter C, Silvestre-Roig C, Ortega-Gomez A, Lemnitzer P, Poelman H, Schumski A, Winter J, Drechsler M, de Jong R, Immler R, Sperandio M, Hristov M, Zeller T, Nicolaes GAF, Weber C, Viola JR, Hidalgo A, Scheiermann C, Soehnlein O. Chrono-pharmacological Targeting of the CCL2-CCR2 Axis Ameliorates Atherosclerosis. Cell Metab. 2018 Jul 3;28(1):175-182.

Ortega-Gomez A, Salvermoser M, Rossaint J, Pick R, Brauner J, Lemnitzer P, Tilgner J, de Jong RJ, Megens RT, Jamasbi J, Döring Y, Pham CT, Scheiermann C, Siess W, Drechsler M, Weber C, Grommes J, Zarbock A, Walzog B, Soehnlein O. Cathepsin G Controls Arterial But Not Venular Myeloid Cell Recruitment. Circulation. 2016; 134:1176-1188.

Alard JE, Ortega-Gomez A, Wichapong K, Bongiovanni D, Horckmans M, Megens RT, Leoni G, Ferraro B, Rossaint J, Paulin N, Ng J, Ippel H, Suylen D, Hinkel R, Blanchet X, Gaillard F, D'Amico M, von Hundelshausen P, Zarbock A, Scheiermann C, Hackeng TM, Steffens S, Kupatt C, Nicolaes GA, Weber C, Soehnlein O. Recruitment of classical monocytes can be inhibited by disturbing heteromers of neutrophil HNP1 and platelet CCL5. Sci Transl Med. 2015; 7:317ra196.

Döring Y, Drechsler M, Wantha S, Kemmerich K, Lievens D, Vijayan S, Gallo RL, Weber C, Soehnlein O. Lack of neutrophil-derived CRAMP reduces atherosclerosis in mice. Circ Res. 2012; 110:1052-6.

Soehnlein O, Wantha S, Simsekyilmaz S, Döring Y, Megens RT, Mause SF, Drechsler M, Smeets R, Weinandy S, Schreiber F, Gries T, Jockenhoevel S, Möller M, Vijayan S, van Zandvoort MA, Agerberth B, Pham CT, Gallo RL, Hackeng TM, Liehn EA, Zernecke A, Klee D, Weber C. Neutrophil-derived cathelicidin protects from neointimal hyperplasia. Sci Transl Med. 2011; 3:103ra98.

Drechsler M, Megens RT, van Zandvoort M, Weber C, Soehnlein O. Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis. Circulation. 2010; 122:1837-45.

Soehnlein O, Zernecke A, Eriksson EE, Rothfuchs AG, Pham CT, Herwald H, Bidzhekov K, Rottenberg ME, Weber C, Lindbom L. Neutrophil secretion products pave the way for inflammatory monocytes. Blood. 2008; 112:1461-71.

Soehnlein O, Kai-Larsen Y, Frithiof R, Sorensen OE, Kenne E, Scharffetter-Kochanek K, Eriksson EE, Herwald H, Agerberth B, Lindbom L. Neutrophil primary granule proteins HBP and HNP1-3 boost bacterial phagocytosis by human and murine macrophages. J Clin Invest. 2008; 118:3491-502.